Andrographolide ameliorates diabetic retinopathy by inhibiting retinal angiogenesis and inflammation

Biochimica et Biophysica Acta - General Subjects

Volumn 1850, Issue 4, 2015, Pages 824-831

  Yu, Zengyang ^a   Lu, Bin ^a   Sheng, Yuchen ^a   Zhou, Lingyu ^a   Ji, Lili ^a   Wang, Zhengtao ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Andrographolide; Angiogenesis; Diabetic retinopathy; Inflammation

Indexed keywords

ANDROGRAPHOLIDE; CD31 ANTIGEN; EARLY GROWTH RESPONSE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; NUCLEAR PROTEIN; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; DITERPENE; EGR1 PROTEIN, MOUSE; STREPTOZOCIN; VASCULOTROPIN A;

ANDROGRAPHIS PANICULATA; ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BLOOD RETINA BARRIER; CONTROLLED STUDY; DIABETIC RETINOPATHY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INFLAMMATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RETINA BLOOD VESSEL; RETINAL ANGIOGENESIS; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; C57BL MOUSE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANDROGRAPHIS PANICULATA; MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DITERPENES; EARLY GROWTH RESPONSE PROTEIN 1; MICE; MICE, INBRED C57BL; NF-KAPPA B; RETINAL VESSELS; STREPTOZOCIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84922222386     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2015.01.014     Document Type: Article

References (44)

1. J.C. Chan, N.H. Cho, N. Tajima, J. Shaw, Diabetes in the Western Pacific Region - past, present and future, Diabetes Res. Clin. Pract. 103 (2014) 244-255.
2. A. Willard, I.M. Herman, Vascular complications and diabetes: current therapies and future challenges, J. Ophthalmol. 2012 (2012) 209538.
3. R.J. Fantes, V.D. Durairaj, S.C. Oliver, Diabetic retinopathy: an update on treatment, Am. J. Med. 123 (2010) 213-216.
4. A.M. Abu EI-Asrar, Evolving strategies in the management of diabetic retinopathy, Middle East Afr. J. Ophthalmol. 20 (2013) 273-282.
5. R. Chibber, B.M. Ben-Mahmud, S. Chibber, E.M. Kohner, Leukocytes in diabetic retinopathy, Curr. Diabetes Rev. 3 (2007) 3-14.
6. C.P. Wilkinson, F.L. Ferris III, R.E. Klein, P.P. Lee, C.D. Agardh, M. Davis, D. Dills, A. Kampik, R. Pararajaseqaram, J.T. Verdaquer, Global Diabetic Retinopathy Project Group, Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales, Ophthalmology 110 (2003) 1677-1682.
7. N. Cheung, P. Mitchell, T.Y. Wong, Diabetic retinopathy, Lancet 376 (2010) 124-136.
8. D. Gologorsky, A. Thanos, D. Vavvas, Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy, Mediat. Inflamm. 2012 (2012) 629452.
9. J.C. Lim, T.K. Chan, D.S. Ng, S.R. Sagineedu, J. Stanslas, W.S. Wong, Andrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer, Clin. Exp. Pharmacol. Physiol. 39 (2012) 300-310.
10. J. Li, L. Luo, X. Wang, B. Liao, G. Li, Inhibition of NF-kappaB expression and allergen-induced airway inflammation in a mouse allergic asthma model by andrographolide, Cell. Mol. Immunol. 6 (2009) 381-385.
11. S.P. Guan, W. Tee, D.S. Ng, T.K. Chan, H.Y. Peh, W.E. Ho, C. Cheng, J.C. Mak, W.S. Wong, Andrographolide protects against cigarette smoke-induced oxidative lung injury via augmentation of Nrf2 activity, Br. J. Pharmacol. 168 (2013) 1707-1718.
12. T. Zhu, W. Zhang, M. Xiao, H. Chen, H. Jin, Protective role of andrographolide in bleomycin-induced pulmonary fibrosis in mice, Int. J. Mol. Sci. 14 (2013) 23581-23596.
13. W. Liu, W. Guo, L. Guo, Y. Gu, P. Cai, N. Xie, X. Yang, Y. Shu, X. Wu, Y. Sun, Q. Xu, Andrographolide sulfonate ameliorates experimental colitis in mice by inhibiting Th1/Th17 response, Int. Immunopharmacol. 20 (2014) 337-345.
14. K. Sheeja, C. Guruvayoorappan, G. Kuttan, Antiangiogenic activity of andrographis paniculata extract and andrographolide, Int. Immunopharmacol. 7 (2007) 211-221.
15. H.H. Lin, C.W. Tsai, F.P. Chou, C.J. Wang, S.W. Hsuan, C.K. Wang, J.H. Chen, Andrographolide down-regulates hypoxia-inducible factor-1α in human non-small cell lung cancer A549 cells, Toxicol. Appl. Pharmacol. 250 (2011) 336-345.
16. K.K. Shen, L.L. Ji, B. Lu, C. Xu, C.Y. Gong, G. Morahan, Z.T. Wang, Andrographolide inhibits tumor angiogenesis via blocking VEGF/VEGFR2-MAPKs signaling cascade, Chem. Biol. Interact. 218 (2014) 99-106.
17. C.Y. Gong, Z.Y. Yu, B. Lu, L. Yang, Y.C. Sheng, Y.M. Fan, L.L. Ji, Z.T. Wang, Ethanol extract of Dendrobium chrysotoxum Lindl ameliorates diabetic retinopathy and its mechanism, Vasc. Pharmacol. 62 (2014) 134-142.
18. C.Y. Gong, B. Lu, Q.W. Hu, L.L. Ji, Streptozotocin induced diabetic retinopathy in rat and the expression of vascular endothelial growth factor and its receptor, Int. J. Ophthalmol. 6 (2013) 573-577.
19. C.X. Huang, Experimental Study of Fufang XueshuanTong on Intervention of Retinopathy in Diabetic Rats, Sun Yat-Sen University, Guangzhou, 2006. 13-19 (In Chinese).
20. V.S. Jeganathan, Anti-angiogenesis drugs in diabetic retinopathy, Curr. Pharm. Biotechnol. 12 (2011) 369-372.
21. B. Kumar, S.K. Gupta, R. Saxena, S. Srivastava, Current trends in the pharmacotherapy of diabetic retinopathy, J. Postgrad. Med. 58 (2012) 132-139.
22. N. Gupta, S. Mansoor, A. Sharma, A. Sapkal, J. Sheth, P. Falatoonzadeh, B. Kuppermann, M. Kenney, Diabetic retinopathy and VEGF, Open Ophthalmol. J. 7 (2013) 4-10.
23. D.A. Antonetti, R. Klein, T.W. Gardner, Diabetic retinopathy, N. Engl. J. Med. 366 (2012) 1227-1239.
24. P.M. Titchenell, D.A. Antonetti, Using the past to inform the future: anti-VEGF therapy as a road map to develop novel therapies for diabetic retinopathy, Diabetes 62 (2013) 1808-1815.
25. G. Tremolada, C.D. Turco, R. Lattanzio, S. Maestroni, A. Maestroni, F. Bandello, G. Zerbini, The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment, Exp. Diabetes Res. 2012 (2012) 728325.
26. J. Waltenberger, L. Claesson-Welsh, A. Siegbahn, M. Shibuya, C.H. Heldin, Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor, J. Biol. Chem. 269 (1994) 26988-26995.
27. A.P. Adamis, Is diabetic retinopathy an inflammtory disease? Brit. J. Ophthalmol. 86 (2002) 363-365.
28. E.C. Leal, J. Martins, P. Voabil, J. Liberal, C. Chiavaroli, J. Bauer, J. Cunha-Vaz, A.F. Ambrosio, Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes, Diabetes 59 (2010) 2637-2645.
29. P.A. Baeuerle, T. Henkel, Function and activation of NF-kappa B in the immune system, Annu. Rev. Immunol. 12 (1994) 141-179.
30. P. Renard, M. Raes, The proinflammatory transcription factor NFkappaB: a potential target for novel therapeutical strategies, Cell Biol. Toxicol. 15 (1999) 341-344.
31. A. Gashler, V. Sukhatme, Egr-1: prototype of a zinc finger family of transcription factors, Prog. Nucleic Acid Res. Mol. Biol. 50 (1995) 191-224.
32. C. Liu, A. Calogero, G. Ragona, E. Adamson, D. Mercola, EGR-1, the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this suppressor activity, Crit. Rev. Oncog. 7 (1996) 1-2.
33. E. Adamson, I. de belle, S. Mittal, Y. Wang, J. Hayakawa, K. Korkmaz, D. O'Hagan, M. McClelland, D. Mercola, Egr1 signaling in prostate cancer, Cancer Biol. Ther. 2 (2003) 617-622.
34. L.M. Khachigian, Early growth response-1 in cardiovascular pathobiology, Circ. Res. 98 (2006) 186-191.
35. S.F. Yan, E. Harja, M. Andrassy, F. Tomoyuki, A.M. Schmidt, Protein kinase C β/Early growth response-1 pathway: a key player in ischemia, atherosclerosis, and restenosis, J. Am. Coll. Cardiol. 48 (2006) A47-A55.
36. A.M. EI-Asrar, L. Missotten, K. Geboes, Expression of high-mobility groups box-1/receptor for advanced glycation and products/osteopontin/early growth response-1 pathway in proliferative vitreoretinal epiretinal membranes, Mol. Vis. 17 (2011) 508-518.
37. A. Aljada, H. Ghanim, P. Mohanty, N. Kapur, P. Dandona, Insulin inhibits the proinflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations, J. Clin. Endocrinol. Metab. 87 (2002) 1419-1422.
38. P. Carmeliet, J.M. Stassen, L. Schoonjans, B. Ream, J.J. van den Oord, M. De Mol, R.C. Mulligan, D. Collen, Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis, J. Clin. Invest. 92 (1993) 2756-2760.
39. Z.L. Zhong, S. Chen, Plasma plasminogen activator inhibitor-1 is associated with end-stage proliferative diabetic retinopathy in the northern Chinese Han population, Exp. Diabetes Res. 2012 (2012) 350852.
40. M.B. Grant, E.A. Ellis, S. Caballero, R.N. Mames, Plasminogen activator inhibitor-1 overexpression in nonproliferative diabetic retinopathy, Exp. Eye Res. 63 (1996) 233-244.
41. P.M. Fernandez, F.R. Rickles, Tissue factor and angiogenesis in cancer, Curr. Opin. Hematol. 9 (2002) 401-406.
42. R.S. Kasthuri, M.B. Taubman, N. Mackman, Role of tissue factor in cancer, J. Clin. Oncol. 27 (2009) 4834-4838.
43. T. Sakamoto, S. Ito, H. Yoshikawa, Y. Hata, T. Ishibashi, K. Sueishi, H. Inomata, Tissue factor increases in the aqueous humor of proliferative diabetic retinopathy, Graefes Arch. Clin. Exp. Ophthalmol. 239 (2001) 865-871.
44. J. Zhang, S. Xie, W. Ma, Y. Teng, Y. Tian, X. Huang, Y. Zhang, A newly identified microRNA, mmu-miR-7578, functions as a negative regulator in inflammatory cytokines tumor necrosis factor-α and interleukin-6 via targeting Egr1 in vivo, J. Biol. Chem. 288 (2013) 4310-4320.